# The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects.

*biotech · news · 2026-04-07 · FinanzNachrichten*

## Key points

- The FDA has approved Eli Lilly's Foundayo (orforglipron) oral GLP-1 tablet for adult obesity.
- Foundayo can be taken at any time, unlike Wegovy, which requires fasting before intake.
- Foundayo showed higher rates of gastrointestinal side effects and discontinuation than semaglutide in trials.
- Lexaria's DehydraTECH technology reduced adverse events by 47.9% with oral semaglutide versus Rybelsus.
- Lexaria plans to test DehydraTECH with new GLP-1 drugs, including retatrutide, amycretin, and possibly orforglipron.

**Companies:** Eli Lilly and Company, Lexaria Bioscience Corp.
**Countries:** United States, Canada

[Read the full story on FinanzNachrichten](https://www.finanznachrichten.de/nachrichten-2026-04/68136997-lexaria-bioscience-corp-lexaria-applauds-eli-lilly-s-foundayo-drug-approval-200.htm)

---

Canonical: https://newsio.io/n/c59f6b1d-bf01-4fb2-b2ed-81bdd9b709f4/the-number-of-oral-weight-loss-diabetes-drug-treatments-is-expanding-increasing
Summarized by Newsio from FinanzNachrichten. https://newsio.io/how-it-works